Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Intangibles (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Intangibles for 4 consecutive years, with $63.8 million as the latest value for Q4 2025.

  • Quarterly Intangibles changed 0.0% to $63.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $63.8 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $63.8 million for FY2025, 0.0% changed from the prior year.
  • Intangibles hit $63.8 million in Q4 2025 for Axsome Therapeutics, up from $42.1 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $63.8 million in Q2 2022 to a low of $42.1 million in Q3 2025.
  • Historically, Intangibles has averaged $57.7 million across 4 years, with a median of $59.7 million in 2022.
  • Biggest five-year swings in Intangibles: grew 19.73% in 2024 and later plummeted 33.97% in 2025.
  • Year by year, Intangibles stood at $59.7 million in 2022, then dropped by 10.69% to $53.3 million in 2023, then increased by 19.73% to $63.8 million in 2024, then changed by 0.0% to $63.8 million in 2025.
  • Business Quant data shows Intangibles for AXSM at $63.8 million in Q4 2025, $42.1 million in Q3 2025, and $63.8 million in Q2 2025.